SOURCE: Optovue, Inc.

Optovue, Inc.

November 13, 2015 09:00 ET

Optovue Showcases Total Cornea Power for Better Eyesight After Cataract Surgery at AAO 2015

AngioVue, Retinal Blood Flow Visualization and Quantification, Highlighted in Symposium and Numerous Scientific Presentations

FREMONT, CA--(Marketwired - Nov 13, 2015) - Optovue, the global leader in the clinical development and commercialization of optical coherence tomography angiography (OCTA), today announced that it will showcase several advanced technologies at AAO 2015, the 119th annual meeting of the American Academy of Ophthalmology, being held in Las Vegas from November 14-17. Total Cornea Power (TCP™) and the AngioVue™* Imaging System with AngioAnalytics™*, are designed to improve disease and procedure management, which may lead to improved outcomes for patients with sight-threatening diseases.

Optovue's TCP technology directly measures the front and back surfaces of the cornea, the transparent layer forming the front of the eye, with accuracy to within 5-microns, or about one-third the width of a human hair. Physicians use data generated by the TCP feature, in combination with other measurements, to determine the correct power of the lens implant. The level of measurement accuracy provided by the TCP technology allows precise selection of lens implant to ensure the patient's vision after surgery is sharp and accurate.

The clinical applications and benefits of the AngioVue System and AngioAnalytics will be the topic of discussion at a breakfast symposium entitled, "The Transformative Power of Quantitative OCT Angiography" being held at The Wynn Las Vegas in the Latour Ballroom on Sunday, November 15. The session is chaired by Jeffrey Heier, MD, director of the vitreoretinal service and the director of retina research at Ophthalmic Consultants of Boston, who will present "OCTA in Clinical Trials: Pro-Con Study Update." Joining him are four key opinion leaders, all with extensive research and clinical experience in OCTA technology. Registration information for the symposium can be found at

David Huang, MD, PhD
Casey Eye Institute, Oregon Health & Sciences University
"New Developments in OCTA Technology"

Nadia Waheed, MD
Retinal Specialist and Associate Professor at Tufts New England Medical School
"Clinical Applications of OCTA"

Pravin Dugel, MD
Retinal Consultants of Arizona
"AngioVue OCT Angiography and Fluorescein Angiography Agreement Study in Identifying the Presence of Choroid Neovascularization"

Richard Rosen, MD
Professor of Ophthalmology, New York Eye and Ear Infirmary, New York Medical College
"OCTA Measurements of Retinal Vessels"

The AngioVue Imaging System embodies OCTA technology, which uses light rays to form detailed three-dimensional images of the retina so physicians can quickly visualize the anatomic structures and presence of abnormalities. In less than three seconds, the AngioVue System acquires a single image that complements the current angiography imaging standard, fluorescein angiography (FA), but with a number of advantages. Unlike FA, the AngioVue System is non-invasive and does not require the use of dye injections, which can often obscure the target anatomy, leading to diagnostic uncertainty. The addition of AngioAnalytics to the AngioVue system provides objective data regarding the areas encompassed by flow and non-flow regions, and creates a flow density map of the blood flow in the retina.

Product demonstrations, the Optovue Education Center, and a booth speaker series are the focus of the Company's booth, #2655. The booth speaker series features presentations by eight industry leading physicians at various times on Saturday and Sunday, November 14 and 15. Additionally, Optovue technology is the focus of 12 scientific presentations. Information about all presentations can be found at

About Optovue
Optovue, Inc., a privately-held medical device company founded in 2003 and based in Fremont, Calif., is dedicated to the development and commercialization of high-speed optical coherence technology used to facilitate the diagnosis and management of eye diseases, many of which may lead to permanent blindness. Since its introduction, the AngioVue Imaging System has been incorporated in to daily clinical use at over 425 sites worldwide. For more information, visit

The AngioVue Imaging System is pending 510(k) clearance in the United States.
AngioAnalytics is not currently cleared for sale in the United States.

Contact Information

  • Media Contact:
    Judy Bartlett-Roberto
    Vice President, Marketing
    Email Contact